477860-13-2

Basic information

• Product Name: 2-fluoro-4-hydroxy-[1,1'-biphenyl]
• CAS NO: 477860-13-2
• Molecular Weight: 188.201
• Mol File: 477860-13-2.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 2-fluoro-4-hydroxy-[1,1'-biphenyl](CAS DataBase Reference)
• NIST Chemistry Reference: 2-fluoro-4-hydroxy-[1,1'-biphenyl](477860-13-2)
• EPA Substance Registry System: 2-fluoro-4-hydroxy-[1,1'-biphenyl](477860-13-2)

Safety Data

• Hazardous Substances Data: 477860-13-2(Hazardous Substances Data)

Upstream product

• 121219-03-2 4-bromo-3-fluorophenol 
• 98-80-6 phenylboronic acid 
• 122927-84-8 3-fluoro-4-iodophenol 
• 178305-99-2 (2-fluoro-[1,1'-biphenyl]-4-yl)boronic acid 
• 41604-19-7 1-bromo-3-fluoro-4-phenylbenzene 
• 37847-52-2 2,4-difluorobiphenyl 
• 550998-23-7 trifluoromethanesulfonic acid 2-fluoro-4-methoxyphenyl ester 
• 167683-93-4 2-fluoro-4-methoxy-phenol 
• 2105-94-4 4-bromo-2-fluorophenol 
• 634192-51-1 2-fluoro-4-methoxy-1,1'-biphenyl 

Relevant articles and documents

(4-HYDROXYPYRROLIDIN-2-YL)-HYDROXAMATE COMPOUNDS AND METHODS OF USE THEREOF

The present disclosure relates to bifunctional compounds, which can be used as modulators of targeted ubiquitination. In particular, the present disclosure is directed to compounds which contain on one end a VHL ligand moiety, which binds to the VHL E3 ubiquitin ligase, and on the other end a moiety that binds a target protein such that degradation of the target protein/polypeptide is effectuated. Also disclosed are VHL ligands.

NOVEL NUCLEOSIDE PHOSPHORAMIDATE COMPOUND AND USE THEREOF

The present invention provides a novel nucleoside phosphoramidate compound, or a stereoisomer, salt, hydrate, solvate or crystal thereof for the treatment of Flaviviridae family viral infection, especially hepatitis C viral infection. The present invention also provides the pharmaceutical composition comprising a compound of the present invention, or a stereoisomer, salt, hydrate, solvate or crystal thereof and a use of the compound or the composition of the present invention in the treatment of Flaviviridae family viral infection, especially hepatitis C viral infection. The compound of the present invention has a good anti-HCV effect.

Preparation of monofluorophenols via the reaction of difluorobenzene derivatives with potassium trimethylsilanoate

An efficient synthesis of monofluorophenols via the reaction of difluorobenzene derivatives with potassium trimethylsilanoate in moderate to excellent yields is described. High regioselectivity was observed in some cases. Georg Thieme Verlag Stuttgart.